Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 11/20 | 0.45 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521917 | 0.81 | KDR (0.40) | KDRMAPK14TNNI3KBRAFRIPK2 | |
| SCHEMBL4273927 | 0.81 | BRAF (0.52) | KDRMAPK14BRAFRAF1 | |
| SCHEMBL1522057 | 0.80 | NPC1 (0.39) | KDRBRAFRAF1MEN1KMT2A | |
| SCHEMBL1521817 | 0.80 | BRAF (0.40) | KDRMAPK14BRAFRAF1MEN1 | |
| SCHEMBL1521993 | 0.79 | KDR (0.39) | KDRMAPK14TNNI3KBRAFRIPK2 | |
| SCHEMBL1521521 | 0.79 | KDR (0.47) | KDRMAPK14TNNI3KBRAFRIPK2 | |
| SCHEMBL1521565 | 0.77 | KDR (0.46) | KDRMAPK14TNNI3KBRAFRIPK2 | |
| SCHEMBL1522036 | 0.77 | TNK2 (0.32) | KDRBRAFRAF1MAPK3 | |
| SCHEMBL1521638 | 0.77 | BRAF (0.47) | KDRMAPK14BRAFRIPK2RAF1 | |
| SCHEMBL1521902 | 0.77 | KDR (0.45) | KDRMAPK14TNNI3KBRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | claimed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | claimed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | claimed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | claimed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | KDR 500/4885MAPK14 240/4885TNNI3K 143/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KDR 500/4885MAPK14 240/4885TNNI3K 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.